Current Price and Recent Price Action
As of 2 June 2026, Dishman Carbogen Amcis Ltd closed at ₹196.95, up from the previous close of ₹194.65. The stock traded within a range of ₹194.05 to ₹202.15 during the day, well below its 52-week high of ₹321.15 but comfortably above its 52-week low of ₹129.00. This price action suggests some short-term resilience, although the stock remains significantly off its peak levels.
Technical Trend Shift: From Sideways to Mildly Bearish
The technical trend for Dishman Carbogen has shifted from a sideways pattern to mildly bearish, signalling a subtle change in momentum. This shift is corroborated by the daily moving averages, which currently indicate a mildly bearish outlook. The stock’s moving averages suggest that recent price gains may be under pressure, with potential resistance ahead if the bearish momentum strengthens.
MACD Analysis: Divergent Signals Across Timeframes
The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On the weekly chart, the MACD remains mildly bullish, indicating some underlying positive momentum in the medium term. However, the monthly MACD is bearish, reflecting longer-term weakness and suggesting that the stock may face downward pressure over the coming months. This divergence between weekly and monthly MACD readings highlights the importance of monitoring multiple timeframes for a comprehensive view.
RSI and Momentum Oscillators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of directional RSI momentum suggests that the stock is neither overbought nor oversold, leaving room for either a rebound or further decline depending on upcoming market catalysts.
Bollinger Bands: Contrasting Weekly and Monthly Views
Bollinger Bands provide additional insight into volatility and price momentum. On the weekly timeframe, the bands are bullish, indicating that the stock price is trending towards the upper band and suggesting short-term strength. Conversely, the monthly Bollinger Bands are mildly bearish, signalling that over a longer horizon, the stock may face downward pressure or consolidation.
KST and Dow Theory: Mixed Technical Landscape
The Know Sure Thing (KST) indicator aligns with the MACD’s mixed signals, showing mild bullishness on the weekly chart but mild bearishness on the monthly chart. Meanwhile, Dow Theory analysis reveals no clear trend on either weekly or monthly timeframes, underscoring the current uncertainty and lack of definitive directional momentum in the stock.
On-Balance Volume and Volume Trends
On-Balance Volume (OBV) indicators on both weekly and monthly charts show no discernible trend, suggesting that volume is not currently confirming price movements. This absence of volume confirmation may imply that recent price changes lack strong conviction from market participants, which could limit the sustainability of any short-term rallies.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Relative Performance Versus Sensex
Examining Dishman Carbogen’s returns relative to the benchmark Sensex reveals a mixed performance over various periods. Over the past week, the stock declined by 1.38%, outperforming the Sensex’s sharper fall of 2.90%. Over one month, the stock gained 7.27%, significantly better than the Sensex’s 3.44% decline. However, year-to-date returns show a steep decline of 20.55%, underperforming the Sensex’s 12.85% loss. Over the past year, the stock’s 26.06% drop contrasts with the Sensex’s more modest 8.82% decline.
Longer-term returns tell a different story. Over three years, Dishman Carbogen has delivered a robust 63.44% gain, substantially outperforming the Sensex’s 18.96% rise. Yet, over five years, the stock’s 1.05% return pales in comparison to the Sensex’s 43.00% gain, indicating recent challenges. Ten-year data for the stock is not available, while the Sensex has surged 178.01% over the same period.
Mojo Score and Rating Update
MarketsMOJO assigns Dishman Carbogen a Mojo Score of 23.0, reflecting a strong sell rating. This is a downgrade from the previous sell rating, effective from 12 January 2026. The downgrade reflects deteriorating technical and fundamental metrics, signalling caution for investors. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and risk.
Implications for Investors
The mixed technical signals suggest that investors should approach Dishman Carbogen with caution. While short-term indicators such as weekly MACD and Bollinger Bands show some bullish tendencies, longer-term monthly indicators and moving averages point to bearish pressures. The absence of clear volume confirmation and neutral RSI readings further complicate the outlook.
Given the stock’s significant underperformance year-to-date and over the past year relative to the Sensex, investors should weigh the risks carefully. The strong sell rating from MarketsMOJO underscores the need for prudence, especially for those with a lower risk tolerance or shorter investment horizon.
Why settle for Dishman Carbogen Amcis Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Outlook and Conclusion
Dishman Carbogen Amcis Ltd’s technical landscape is characterised by a delicate balance between short-term bullish signals and longer-term bearish trends. The mildly bearish shift in momentum, combined with a strong sell rating and underwhelming recent returns, suggests that the stock may face headwinds in the near term.
Investors should monitor key technical indicators closely, particularly the monthly MACD and moving averages, for signs of further deterioration or potential recovery. Additionally, volume trends and RSI movements will be critical in confirming any sustained directional moves.
For those considering exposure to the Pharmaceuticals & Biotechnology sector, it may be prudent to explore alternative small-cap opportunities with stronger technical and fundamental profiles, as highlighted by comparative evaluations within the sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
